The optimal intravesical maintenance chemotherapy scheme for the intermediate-risk group non-muscle-invasive bladder cancer
Abstract Objective Although the current European Association of Urology(EAU) guideline recommends that patients with intermediate-risk non-muscle-invasive bladder cancer (NMIBC) should accept intravesical chemotherapy or Calmette-Guerin (BCG) for no more than one year after transurethral resection o...
Main Authors: | Jian-Xin Chen, Wen-Ting Huang, Qing-Yun Zhang, Cheng-En Deng, Jue-ling Wei, Yuan-Liang Xie, Rui Lin, Guan-Zheng Feng, Guang-Lin Yang, Jun Long, Hao-Yuan Lu, Zeng-nan Mo |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-10-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12885-023-11523-9 |
Similar Items
-
Intravesical adriamycin in the management of bladder tumours Enugu experience
by: Aloy E Aghaji, et al.
Published: (1996-01-01) -
Development and investigation of a novel device with gemcitabine for hyperthermic intravesical chemotherapy
by: Li Jing, et al.
Published: (2023-12-01) -
Instillation Strategies for Non-Muscle-Invasive Bladder Cancer in the Bacillus Calmette-Guerin Shortage Era: A Simple Solution for BCG Discontinuation
by: Lin PT, et al.
Published: (2022-11-01) -
3-year experience of hyperthermic intravesical chemotherapy use in patients with high risk non-muscular-invasive bladder cancer
by: R.S. Chystiakov, et al.
Published: (2023-06-01) -
Application of intra-arterial chemotherapy in high-risk non-muscle invasive bladder cancer: a systematic review and meta-analysis
by: Chengyu You, et al.
Published: (2021-09-01)